
GSK’s $30 Billion U.S. Pharma Investment: Strategic Move Amid Trump’s State Visit
GlaxoSmithKline (GSK), one of the United Kingdom’s largest drugmakers, has announced a landmark $30 billion investment in the United States. This bold decision, unveiled during former U.S. President Donald Trump’s state visit to London, carries both economic and geopolitical weight, signaling how healthcare, politics, and global trade remain deeply intertwined.








